Rgenta Therapeutics has initiated a Phase 1a/b clinical trial of RGT-61159, an oral small molecule targeting MYB, in patients with advanced adenoid cystic carcinoma (ACC) and colorectal cancer (CRC).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.